BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

Background Many observational studies highlight clonal haematopoiesis (CH) as a novel determinant of cardiovascular disease ...

Scientists at UCSF identified a key cellular switch that plays a large role in pulmonary fibrosis, and found a way of ...

Researchers developed PVC, a measure that estimates the reduced function of the pulmonary arteries in pediatric PAH patients, ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...

A female infant presented with a month-long history of dry cough, along with two episodes of fever and increased work of ...

The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and foundation will form a joint steering committee.